Aug 1 (Reuters) - U.S. drugmaker Eli Lilly ( LLY )

expects its blockbuster weight-loss drug to officially come out

of shortage in the United States in coming days, Bloomberg News

reported on Thursday, citing an interview with the company's

chief executive officer, David Ricks.

Lilly's drug, tirzepatide, sold as Mounjaro for diabetes and

Zepbound for weight management, will cease to be in shortage

"very soon," CEO David Ricks said in an interview with Bloomberg

in Paris.